A two-week treatment with benznidazole for adults with chronic Chagas disease has similar efficacy and significantly fewer adverse effects than the current standard eight-week treatment, according to a study published by The Lancet Infectious Diseases.
These results are extracted from a Phase II clinical trial that was carried out in three centres in Bolivia, led by the Drugs for Neglected Diseases initiative (DNDi) and funded by the Global Health Innovative Technology Fund (GHIT).
The trial was carried out between 2016 and 2018, in cooperation with many partners around the globe, including the Bolivian CEADES (Science and Applied Studies Foundation for Health and Environment Development), the Barcelona Institute for Global Health (ISGlobal) –a centre supported by ”La Caixa” foundation-, the Japanese pharmaceutical company Eisai Co., Ltd. and the Argentinian pharmaceutical company Elea Phoenix S.A.